The Associated Press on MSN4d
A promising schizophrenia drug showed mixed results. What does that mean for patients?Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...
Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...
In September, the FDA approved the drug previously known as KarXT as a novel antipsychotic therapy for adults with schizophrenia. Citing new topline data from its 52-week open-label studies ...
Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...
As journalist Brian Reid notes, Medicaid covers 70% of schizophrenia patients. Federal law requires that the program receive a rebate of 23.1% off any drug's best price. So they'll get the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback